{
    "2018-12-03": [
        [
            {
                "time": "2018-01-02",
                "original_text": "AbbVie Stock Could Become a New Happy Pill for Investors",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Stock",
                        "Happy Pill",
                        "Investors"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "IMBRUVICAÂ® (ibrutinib) Phase 3 Combination Data with Obinutuzumab Finds Significant Improvement in Progression-Free Survival (PFS) Over Standard Chemoimmunotherapy of Chlorambucil Plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)",
                "features": {
                    "keywords": [
                        "IMBRUVICA",
                        "Phase 3",
                        "Obinutuzumab",
                        "Progression-Free Survival",
                        "Chronic Lymphocytic Leukemia"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "oncology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "XLV, PFE, MRK, ABBV: ETF Inflow Alert",
                "features": {
                    "keywords": [
                        "XLV",
                        "PFE",
                        "MRK",
                        "ABBV",
                        "ETF",
                        "Inflow"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "ETFs"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "AbbVie Settles With Pfizer for Humira Biosimilar in U.S.",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Pfizer",
                        "Humira",
                        "Biosimilar",
                        "Settlement"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "AbbVie's Imbruvica Achieves Up to 7-Year Progression-Free Survival in Leukemia Patients",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Imbruvica",
                        "Progression-Free Survival",
                        "Leukemia"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "oncology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "AbbVie Presents Long-Term Data on Cancer Drugs at ASH 2018",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Long-Term Data",
                        "Cancer Drugs",
                        "ASH 2018"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "oncology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "Today's Research Reports on Trending Tickers: AbbVie and OPKO Health",
                "features": {
                    "keywords": [
                        "Research Reports",
                        "Trending Tickers",
                        "AbbVie",
                        "OPKO Health"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}